Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06103669 · ClinicalTrials.gov registry record · NA

Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)

A NA study of Breast Cancer and Head and Neck Cancer, sponsored by University of California, Davis.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
1
Study location

NCT06103669: Recruiting NA study of Breast Cancer and Head and Neck Cancer, sponsored by University of California, Davis.

NCT06103669 is a NA study of Breast Cancer and Head and Neck Cancer that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 250 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06103669, a NA study of Breast Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by University of California, Davis.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
1
Study location

Study Summary

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

Primary Outcome

Number of participants with controlled disease at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy

Interventions

  • DEVICE Ablative local therapy

Study Locations (1)

California

  • University of California, Davis - Sacramento

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2023-10-05
Est. Completion 2031-01-05
Phase NA
University of California, Davis

657 total trials

What NCT06103669 shows while recruiting

NCT06103669 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower).

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ablative local therapy is the first listed.

NCT06103669 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06103669 about?

NCT06103669 is a clinical study titled "Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)". This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in...

What is the current status of trial NCT06103669?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2023-10-05. Estimated completion is 2031-01-05.

What conditions does trial NCT06103669 study?

This clinical trial studies the following conditions: Breast Cancer, Head and Neck Cancer, Sarcoma, Other Cancer, Oligoprogressive.

What interventions are being tested in trial NCT06103669?

The interventions under investigation include: Ablative local therapy (DEVICE).

Who is sponsoring clinical trial NCT06103669?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06103669 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06103669's enrollment target sits among peer trials

250 323rd of 1224 higher than 895 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06103669, the US trial registry maintained by the National Library of Medicine. NCT06103669 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.